Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
The Food and Drug Administration has approved Spark Therapeutics' Luxturna, the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.
The treatment would help those with Leber congenital amaurosis, a rare genetic retinal disease. It's specifically approved for people who have a mutated RPE65 gene, which is vital to creating an enzyme needed for normal vision. A faulty one can make the gene less active or inactive, leading to impaired vision and even complete blindness.
Luxturna uses a modified virus to deliver a healthy copy of the gene directly to a patient's retinal cells through eye surgery. The working copy then replaces the broken one to spark production of the necessary enzymes to restore the patient's vision.
"Today's approval marks another first in the field of gene therapy — both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss — and this milestone reinforces the potential of this breakthrough approach in treating a wide-range of challenging diseases," FDA Commissioner Scott Gottlieb said in a statement.
Luxturna is the third gene therapy approved by the FDA.
The agency's approval of Luxturna was widely expected. Spark Therapeutics shares rose as much as 6.8 percent before turning negative and closing down 0.2 percent on the day.